High Intensity Focused Ultrasound Tumor Therapy System and Its Application

2007 ◽  
Author(s):  
Fucheng Sun ◽  
Ye He ◽  
Rui Li
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
Tumor Therapy ◽  
High Intensity Focused Ultrasound

High intensity focused ultrasound in the treatment of small kidney tumours— The Oxford experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14645-14645
Author(s):  
T. A. Leslie ◽  
R. O. Illing ◽  
J. E. Kennedy ◽  
M. F. Wu ◽  
G. R. Ter Haar ◽  
...  
Keyword(s):  
Mr Imaging ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Tumor Therapy ◽  
Prospective Trial ◽  
Tumour Response ◽  
Skin Toxicity ◽  
High Intensity Focused Ultrasound ◽  
Initial Assessment ◽  
Renal Tumours

14645 Background: High-intensity focused ultrasound (HIFU) provides a potential non-invasive alternative to conventional therapies. We have been using the extracorporeal ultrasound-guided Model-JC Tumor Therapy System (HAIFU Technology Company, China) in clinical trials to evaluate the safety and feasibility of treating small renal tumours. Methods: Patients with renal tumours less than 4cm diameter and unsuitable for surgery were treated with HIFU were enrolled into this phase II prospective trial. Treatment was delivered under general anaesthesia in a single session using the Model-JC Tumor Therapy System. Magnetic resonance imaging (MRI) 12 days after treatment provided an initial assessment of response (technical success). Patients are followed-up with further MR imaging at 6 months and one year to gauge technique effectiveness. A total of 14 patients will be included in the trial. Results: Eight patients with kidney tumours have been treated to date. All eight have had pre- and 12-day post-treatment MR imaging. One patient was not included in the analysis as treatment was suspended due bowel interposition in the treatment field during therapy. MRI changes suggestive of kidney tumour response have been seen in 4/7 (57%) cases. Complete ablation has been seen in two cases and partial ablation in two cases. One patient remains disease free 12 months after HIFU. Mild transient discomfort was reported by 4/8 patients (50%), and moderate discomfort in 3/8 (38%) but more severe pain needing opiate analgesia has not been encountered in this series. Minor skin toxicity (1mm blister at the treatment site) was seen in two patients. All patients were discharged the day after the procedure. There have been no adverse effects on renal, haematological or hepatic function. Conclusions: Extracorporeal HIFU has the ability to completely ablate small renal tumours. Our early clinical experience suggests that HIFU treatment of kidney tumours is safe and extremely well tolerated. The reasons for the variability in observed response remain obscure, and reliability of tumour ablation will need to improve before extracorporeal HIFU can be proposed for wider clinical use. [Table: see text]

DESIGN AND FABRICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND PHASED ARRAY FOR LIVER TUMOR THERAPY

2009 ◽  
Vol 21 (03) ◽  
pp. 187-192 ◽  
Author(s):  
Gin-Shin Chen ◽  
Jonathan Cannata ◽  
Ruibin Liu ◽  
Hsu Chang ◽  
K. Kirk Shung
Keyword(s):  
Liver Tumor ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Phased Array ◽  
Liver Tumors ◽  
Tumor Therapy ◽  
Electrical Power ◽  
Preliminary Test ◽  
Central Line ◽  
High Intensity Focused Ultrasound

Noninvasive surgery of the liver tumors has been carried out by using the high-intensity focused ultrasound (HIFU). However, the liver tumor can be moved by the human respirations and heartbeats, which may cause the ablation and damage of normal tissues during the sonications of HIFU. The purpose of this study was to design and fabricate a cylindrical HIFU phased array transducer for treating the moving liver tumor efficiently. The total number of the element was 512 but only 256 channels were required since the elements along the elevation direction were connected in pairs with respect to the central line of the array. Field II software was used to simulate the acoustic field, and a formula for predicting the spatial averaged intensity at focus was developed based on the practical factors. The results of the simulations showed that the cylindrical HIFU phased array in water had a dynamic focusing range from 145 to 175 mm in the depth direction and a steering range from -15 to 15 mm in azimuthal direction with respect to the center of the array. After the dissipation of cables and the attenuation of various media, the designed array could still generate the intensity at focus up to 1095 W/cm2 when the input electrical power was approximately 410 W. The prototype of the array was fabricated and the preliminary test was completed. The testing results showed that each element of the array prototype can work well.

1400: Early Clinical Experience Using High-Intensity Focused Ultrasound for the Treatment of Renal Tumours

2005 ◽  
Vol 173 (4S) ◽  
pp. 379-380
Author(s):  
James E. Kennedy ◽  
Rowland O. Illing ◽  
Feng Wu ◽  
Gail R. ter Haar ◽  
Rachel R. Phillips ◽  
...  
Keyword(s):  
Clinical Experience ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Early Clinical Experience ◽  
Renal Tumours

Das Prostatakarzinom: aktuelle Diagnostik und Therapiestandard

Praxis ◽  
2016 ◽  
Vol 105 (16) ◽  
pp. 971-977
Author(s):  
Jan Brachlow ◽  
Martin Kälin ◽  
Marco Randazzo ◽  
Beat Förster ◽  
Hubert John
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Psa Test ◽  
Eine Hohe ◽  
Psa Screening ◽  
Sekundäre Hormontherapie

Zusammenfassung. Das Prostatakarzinom zeigt eine hohe Prävalenz und ist daher für die behandelnden Ärzte medizinisch, aber auch gesundheitspolitisch relevant. PSA-Screening senkt die karzinomspezifische Mortalität, ist jedoch aufgrund der hohen Prävalenz mit einer Überdiagnostik verbunden. Dies fordert im Gegenzug einen verantwortungsbewussten Umgang mit dem PSA-Test («smarter screening»). Durch die robotergestützte Prostatektomie steht eine Therapie mit geringer Morbidität zur Behandlung des lokalisierten Prostatakarzinoms zur Verfügung. Das fokale Behandlungskonzept der HIFU (high-intensity focused ultrasound) ist vielversprechend, jedoch noch klinisch experimentell und sollte im Rahmen von Studien angeboten werden. Die Behandlungsmöglichkeiten beim metastasierten Prostatakarzinom wurden entscheidend vervielfältigt. Chemotherapie und die sekundäre Hormontherapie werden voraussichtlich vermehrt in früheren Phasen der Krankheit eine Rolle spielen, wodurch die Therapie für den einzelnen Patienten immer komplexer wird und individuell angepasst werden muss.

Sign in / Sign up

Export Citation Format

Share Document